[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444256":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":16,"studyPopulation":17,"armGroups":13,"interventions":18,"overallOfficials":21,"centralContacts":29,"locations":34,"responsibleParty":52,"collaborators":13,"id":55,"slug":13,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":13,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":13,"enrollmentInfo":64,"targetDuration":13,"studyType":67,"phases":13,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":37,"whyStopped":13,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Michael J. Fox Foundation for Parkinson's Research","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Unified Parkinson's Disease Rating Scale Ib & II","Evaluates self-reported motor and nonmotor Parkinson's disease symptoms","Baseline to 240 months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":6,"maskingInfo":13},"COHORT","PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical \\[NCT04477785\\], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation","In PPMI Online, up to 500,000 participants with and without PD will be enrolled and contribute data longitudinally and cross-sectionally using a web-based platform.",[19],{"type":6,"name":20,"description":20,"armGroupLabels":13,"otherNames":13},"Observation",[22,26],{"name":23,"affiliation":24,"role":25},"Caroline Tanner, MD, PhD","University of California, San Francisco","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":28,"role":25},"Kenneth L Marek, MD","Institute for Neurodegenerative Disorders",[30],{"name":24,"role":31,"phone":32,"phoneExt":13,"email":33},"CONTACT","877-525-7764","info@ppmionline.org",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"UCSF Movement Disorders and Neuromodulation Center (MDNC)","RECRUITING","San Francisco","California","94143","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-122.41942,37.77493,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":32,"phoneExt":13,"email":13},"UCSF",{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":24,"oldNameTitle":13,"oldOrganization":13},"Caroline M Tanner","Protocol Co- Principal Investigator","100444256",false,"NCT05065060","Parkinson Progression Marker Initiative Online (PPMI Online)","Parkinson's Progression Markers Initiative Online Study (PPMI Online)","Inclusion Criteria:\n\n* Parkinson Disease (PD) Participants:\n\n  * Male or female age 18 years or older.\n  * Has received a diagnosis of Parkinson's disease\n\nParticipants without PD:\n\n* Male or female age 18 years or older.\n* Has not received a diagnosis of Parkinson's disease",true,"ALL","18 Years",{"count":65,"type":66},500000,"ESTIMATED","OBSERVATIONAL","Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.\n\nPPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.",[70],"Parkinson Disease",[72,73,74,75,76],"Parkinson","Neurodegenerative Disorder","Prodromal","At Risk","Participant Reported Outcomes","2024-11-21",{"date":79,"type":80},"2024-11-25","ACTUAL",{"date":82,"type":80},"2021-07-28",{"date":84,"type":66},"2041-12",{"name":5,"class":6},1]